AUTHOR=Zhao Xiaoxia , Yang Siyu , Lei Ruining , Duan Qiaoyan , Li Jundong , Meng Jiangtao , Sun Lei 

TITLE=Clinical study on the feasibility of new thrombus markers in predicting massive cerebral infarction

JOURNAL=Frontiers in Neurology

VOLUME=Volume 13 - 2022

YEAR=2023

URL=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2022.942887

DOI=10.3389/fneur.2022.942887

ISSN=1664-2295

ABSTRACT=Objective This study investigated the diagnostic performance of thrombin-antiprothrombin complex (TAT), plasmin-α2 plasmin inhibitor complex (PIC), tissue plasminogen activator-plasminogen activator inhibitor complex (t-PAIC) and thrombomodulin (TM) in early identification of massive cerebral infarction. Method A total of 423 patients with cerebral infarction confirmed by imaging examination were divided into massive cerebral infarction group (MCI) and non-massive cerebral infarction group (NMCI). TAT, PIC, t-PAIC and TM were measured immediately after admission. The diagnostic performance was analyzed by receiver characteristic operating curve (ROC). Result The plasma concentrations of TAT, PIC, and t-PAIC in patients at early stage of MCI were higher than those in NMCI patients, and the difference was statistically significant (P < 0.001), and ROC curve analysis showed that PIC had the best performance in identifying MCI at early stage (area under the curve, AUC = 82.8%), with a sensitivity of 80.7% and a specificity of 76.2% when the PIC concentration was ≥0.8μg/mL; TAT had the highest specificity in identifying MCI, with a specificity of 80.6% when the TAT concentration was ≥3.97ng/mL. Conclusion The increased concentrations of TAT, PIC, and t-PAIC in patients at early stage of MCI have diagnostic value in identifying MCI patients and can be used as serum markers for early identification of macrovascular occlusion.